Lilly Company Profile

✉ Email this page to a colleague

LILLY has one hundred and five approved drugs.

There is one US patent protecting LILLY drugs.

There are thirty patent family members on LILLY drugs in twenty-five countries and eighty-seven supplementary protection certificates in thirteen countries.

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	MOXAM	moxalactam disodium	INJECTABLE;INJECTION	050550-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Lilly	ONCOVIN	vincristine sulfate	INJECTABLE;INJECTION	014103-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No		⤷ Subscribe				⤷ Subscribe
Lilly	AVENTYL HYDROCHLORIDE	nortriptyline hydrochloride	CAPSULE;ORAL	014684-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
Lilly	HALDRONE	paramethasone acetate	TABLET;ORAL	012772-006	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Subscribe				⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Lilly	FORTEO	teriparatide	SOLUTION;SUBCUTANEOUS	021318-001	Nov 26, 2002	7,163,684	⤷ Subscribe
Lilly	PROZAC	fluoxetine hydrochloride	TABLET;ORAL	020974-001	Mar 9, 1999	4,626,549*PED	⤷ Subscribe
Lilly	CIALIS	tadalafil	TABLET;ORAL	021368-004	Jan 7, 2008	7,182,958*PED	⤷ Subscribe
Lilly	PROZAC	fluoxetine hydrochloride	SOLUTION;ORAL	020101-001	Apr 24, 1991	4,626,549*PED	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Delayed-release Capsules	40 mg	➤ Subscribe	2012-05-10
➤ Subscribe	Capsules	6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg and 12 mg/50 mg	➤ Subscribe	2005-01-10
➤ Subscribe	For Injection	200 mg/vial	➤ Subscribe	2005-11-01
➤ Subscribe	For Injection	2 g/vial	➤ Subscribe	2007-08-24
➤ Subscribe	For Injection	500 mg/vial	➤ Subscribe	2008-02-04
➤ Subscribe	For Injection	750 mg/vial	➤ Subscribe	2016-10-06
➤ Subscribe	Tablets	2.5 mg	➤ Subscribe	2008-10-14
➤ Subscribe	Delayed-release Capsules	20 mg, 30 mg and 60 mg	➤ Subscribe	2008-08-04
➤ Subscribe	Capsules	10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg and 100 mg	➤ Subscribe	2007-05-29
➤ Subscribe	Capsules	3 mg/25 mg	➤ Subscribe	2008-05-08
➤ Subscribe	For Injection	1g/vial	➤ Subscribe	2005-11-14
➤ Subscribe	For Injection	100 mg/vial	➤ Subscribe	2008-07-01
➤ Subscribe	For Injection	1000 mg/vial	➤ Subscribe	2012-06-27
➤ Subscribe	Injection	250 mcg/mL, 2.4 mL prefilled Pen	➤ Subscribe	2015-07-27
➤ Subscribe	Tablets	5 mg, 10 mg and 20 mg	➤ Subscribe	2007-11-21

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
Eurasian Patent Organization	009497	⤷ Subscribe
Spain	2369671	⤷ Subscribe
Norway	20064955	⤷ Subscribe
Eurasian Patent Organization	200601801	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Subscribe
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2782584	21C1058	France	⤷ Subscribe	PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), Y COMPRIS SOUS FORME HEMIHYDRATEE, ET DE LA PROGESTERONE; NAT. REGISTRATION NO/DATE: NL51886 20210421; FIRST REGISTRATION: BE - BE582231 20210406
0253310	SPC/GB95/010	United Kingdom	⤷ Subscribe	PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
1280520	CA 2015 00017	Denmark	⤷ Subscribe	PRODUCT NAME: TOBRAMYCIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/10/652/001-003 20110720
0740668	03C0017	France	⤷ Subscribe	PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.